Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab
with Naval Daver, MD

767. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study
Daver N, Pollyea D, Carcia J, et al. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. ASH 2018. Abstract 767.
https://ash.confex.com/ash/2018/webprogram/Paper116013.html

906. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
Daver N, Garcia-Manero G, Basu S, et al. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. ASH 2018. Abstract 906.
https://ash.confex.com/ash/2018/webprogram/Paper120157.html

Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and Relapsed/Refractory AML
with Mark J. Levis, MD, PhD

563. Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Cortes J, Khaled S, Martinelli G, et al. Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. ASH 2018. Abstract 563.
https://ash.confex.com/ash/2018/webprogram/Paper110439.html

564. Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
Pratz K, Cherry M, Altman J, et al. Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH 2018. Abstract 564.
https://ash.confex.com/ash/2018/webprogram/Paper110975.html

The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs
with Daniel A. Pollyea, MD

285. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy
Pollyea D, Pratz K, Jonas B. et al. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. ASH 2018. Abstract 285.
https://ash.confex.com/ash/2018/webprogram/Paper117179.html

284. Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy
Wei A, Strickland S, Hou J, et al. Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. ASH 2018. Abstract 284.
https://ash.confex.com/ash/2018/webprogram/Paper118729.html

The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results
with Farhad Ravandi, MD

25. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Ravandi F, Stein A, Kantarjian H, et al. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). ASH 2018. Abstract 25.
https://ash.confex.com/ash/2018/webprogram/Paper109762.html

763. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Ravandi F, Bashey A, Foran J, et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study. ASH 2018. Abstract 763.
https://ash.confex.com/ash/2018/webprogram/Paper119786.html

Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients?
with Eytan M. Stein, MD

560. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Stein E, DiNardo C, Fathi A, et al. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. ASH 2018. Abstract 560.
https://ash.confex.com/ash/2018/webprogram/Paper110449.html

561. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Roboz G, DiNardo C, Stein E, et al. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. ASH 2018. Abstract 561.
https://ash.confex.com/ash/2018/webprogram/Paper110595.html

Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML?
with Eunice S. Wang, MD

26. Maturing Clinical Profile of IMGN779. A Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Cortes J, DeAngelo D, Erba H, et al. Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. ASH 2018. Abstract 26.
https://ash.confex.com/ash/2018/webprogram/Paper112891.html

2647. Synergistic Anti-Leukemic Activity of PARP Inhibition Combine with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models
Fritz C, Portwood S, Adams J, et al. Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models. ASH 2018. Abstract 2647.
https://ash.confex.com/ash/2018/webprogram/Paper117214.html